[HTML] sciencedirect.comFull View

[HTML][HTML] Altered Fc glycosylation of anti‐HLA alloantibodies in hemato‐oncological patients receiving platelet transfusions

TLJ van Osch, T Pongracz, DM Geerdes, JY Mok… - Journal of Thrombosis …, 2022 - Elsevier
Background The formation of alloantibodies directed against class I human leukocyte
antigens (HLA) continues to be a clinically challenging complication after platelet …
被引用次数：8 相关文章

Altered Fc glycosylation of anti-HLA alloantibodies in hemato-oncological patients receiving platelet transfusions

TLJ van Osch, T Pongracz… - … of thrombosis and …, 2022 - pubmed.ncbi.nlm.nih.gov
Background The formation of alloantibodies directed against class I human leukocyte
antigens (HLA) continues to be a clinically challenging complication after platelet …
[PDF] researchgate.net

[PDF][PDF] Altered Fc glycosylation of anti-HLA alloantibodies in hemato-oncological patients receiving platelet transfusions

TLJ van Osch, T Pongracz, DM Geerdes, JY Mok… - 2022 - researchgate.net
Background: The formation of alloantibodies directed against class I human leukocyte
antigens (HLA) continues to be a clinically challenging complication after platelet …
[HTML] jthjournal.org

[HTML][HTML] Altered Fc glycosylation of anti‐HLA alloantibodies in hemato‐oncological patients receiving platelet transfusions

TLJ van Osch, T Pongracz, DM Geerdes… - Journal of Thrombosis …, 2022 - jthjournal.org
Background The formation of alloantibodies directed against class I human leukocyte
antigens (HLA) continues to be a clinically challenging complication after platelet …

Altered Fc glycosylation of anti-HLA alloantibodies in hemato-oncological patients receiving platelet transfusions.

TLJ van Osch, T Pongracz, DM Geerdes… - … of Thrombosis and …, 2022 - europepmc.org
Background The formation of alloantibodies directed against Class I Human Leukocyte
Antigens (HLA) persists to be a clinically challenging complication after platelet transfusions …

Altered Fc glycosylation of anti‐HLA alloantibodies in hemato‐oncological patients receiving platelet transfusions

TLJ van Osch, T Pongracz, DM Geerdes… - … of Thrombosis and …, 2022 - Wiley Online Library
Background The formation of alloantibodies directed against class I human leukocyte
antigens (HLA) continues to be a clinically challenging complication after platelet …

Altered Fc glycosylation of anti-HLA alloantibodies in hemato-oncological patients receiving platelet transfusions

TLJ van Osch, T Pongracz… - Journal of …, 2022 - researchinformation.amsterdamumc …
Background: The formation of alloantibodies directed against class I human leukocyte
antigens (HLA) continues to be a clinically challenging complication after platelet …
[PDF] universiteitleiden.nl

[PDF][PDF] Altered Fc glycosylation of anti-HLA alloantibodies in hemato-oncological patients receiving platelet transfusions

TLJ van Osch, T Pongracz, DM Geerdes… - 2022 - scholarlypublications …
Background: The formation of alloantibodies directed against class I human leukocyte
antigens (HLA) continues to be a clinically challenging complication after platelet …
[HTML] nih.gov

[HTML][HTML] Altered Fc glycosylation of anti‐HLA alloantibodies in hemato‐oncological patients receiving platelet transfusions

TLJ van Osch, T Pongracz, DM Geerdes… - … of Thrombosis and …, 2022 - ncbi.nlm.nih.gov
Background The formation of alloantibodies directed against class I human leukocyte
antigens (HLA) continues to be a clinically challenging complication after platelet …

Altered Fc glycosylation of anti-HLA alloantibodies in hemato-oncological patients receiving platelet transfusions

TLJ van Osch, T Pongracz… - Journal of …, 2022 - scholarlypublications …
Background The formation of alloantibodies directed against class I human leukocyte
antigens (HLA) continues to be a clinically challenging complication after platelet …